Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.560
-0.080 (-4.88%)
At close: Feb 21, 2025, 4:00 PM
1.610
+0.050 (3.21%)
After-hours: Feb 21, 2025, 6:27 PM EST
Outlook Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
49.95M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OTLK News
- 3 days ago - Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 8 days ago - Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire
- 18 days ago - Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 22 days ago - Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga
- 5 weeks ago - Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewsWire